"Ozempic personality" is a phrase, not a finding. It is used in media and online for people who say a GLP-1 drug made them less interested in things they used to enjoy, flatter in mood, or less driven. No published study uses the term. The questions underneath it — whether these drugs change pleasure and motivation beyond food — are real, and the evidence on them is thin and pulls in more than one direction.
This page documents what exists. Every search and document below was read on 15 October 2026. The separate, much larger record on depression and suicidal thoughts is on GLP-1 and depression, and the food-specific construct is on food noise; this page does not repeat either.
A census: what has been published
| Search (15 October 2026) | Records |
|---|---|
| PubMed, "ozempic personality" in title or abstract | 0 |
| PubMed, "ozempic" and "personality" in title or abstract | 0 |
| PubMed, semaglutide / tirzepatide / liraglutide / GLP-1 receptor agonist and anhedonia | 6 |
| PubMed, the same drugs and apathy or "emotional blunting" | 4 |
| ClinicalTrials.gov, "anhedonia semaglutide" / "anhedonia tirzepatide" | 0 trials measuring anhedonia during weight treatment |
Of the six anhedonia records, two are animal studies, two are reviews, one is a 2026 review of mood disorders and suicide risk, and one is a case series. The registry searches returned studies in cocaine, methamphetamine and alcohol use and in muscle preservation — none designed to measure pleasure or motivation in people taking the drugs for weight.
The absence is the main finding. A claim repeated widely online has no controlled study behind it, in either direction.
What the labels say
The current Wegovy label (June 2026) and Zepbound label (August 2026) contain no entry for anhedonia, apathy, emotional blunting or mood change in their adverse-reaction tables or their warnings — glp1ledger searched the label text for each term. The suicidal-thoughts warning these labels used to carry was removed in early 2026 after an FDA review; that history, and what the review measured, is on our depression page.
A label lists what was reported often enough in trials, or flagged in post-marketing review, to warrant an entry. An effect that trial questionnaires never asked about can be absent from a label without being absent from patients.
The case reports
Two published reports describe something close to what the phrase means.
A 2026 case series of three women on tirzepatide 15 mg (Obesity Pillars) reported reduced motivation, emotional "flatness" and loss of interest in exercise and previously enjoyable activities, despite successful weight loss. Two had no history of mood disorder; one had a history of depression and anxiety. The authors describe the symptoms as distinct from depressive episodes and as emerging after prolonged treatment at or near the top dose. All three had the dose lowered to 10 mg or less: two improved on that alone, one also received bupropion. In one, raising the dose again brought the symptoms back without further weight loss, and lowering it again reversed them. The authors' own framing of the wider picture: "some patients anecdotally report" these symptoms during high-dose therapy.
A 2025 case report (BMJ Case Reports) describes an older woman with dementia and type 2 diabetes who developed apathy, marked weight loss and loss of appetite after starting semaglutide; the symptoms improved after it was stopped.
What these can and cannot show: case reports describe what happened to particular people. They cannot say how often it happens, whether the drug caused it, or whether the same people would have reported the same change without the drug. Three people and one person are where a question starts.
Why the idea is plausible: the reward evidence
The reason the claim is taken seriously is that GLP-1 drugs demonstrably act on the brain's reward circuitry — for food, and in trials for alcohol.
- Food cues. A 2014 brain-imaging study of 48 people (Diabetes) found that an intravenous GLP-1 drug reduced responses to food pictures in the insula, amygdala, putamen and orbitofrontal cortex — regions involved in appetite and reward — and that blocking the GLP-1 receptor largely removed the effect. It measured responses to food only.
- Alcohol, a 9-week trial. In 48 adults with alcohol use disorder (JAMA Psychiatry, 2025), low-dose semaglutide reduced the alcohol consumed in a laboratory drinking session, drinks per drinking day and weekly craving, though not overall drinking days.
- Alcohol, a 26-week trial. In 108 people with alcohol use disorder and obesity (Lancet, 2026), heavy drinking days fell 41.1 percentage points on semaglutide 2.4 mg against 26.4 on placebo, a difference of 13.7 points.
These results show the drugs can change how rewarding food and alcohol are. They do not show the drugs reduce pleasure from music, company, exercise or work — the things people describe when they use the phrase. That extension is the untested step. More on the alcohol trials is on GLP-1 and alcohol.
The evidence that points the other way
A 2025 systematic review of GLP-1 drugs for psychiatric symptoms (Brain and Behavior, nine randomised trials) reported that liraglutide 1.8 mg a day improved depression and anhedonia scores in people with mood disorders. So the same drug class has case reports of flatness and a trial signal of improvement — in different people, measured differently.
What has never been tested
- How common it is. No study has asked a representative group of people on GLP-1 drugs about pleasure or motivation using a validated scale.
- Dose. The case series points to the highest tirzepatide dose; no trial has compared doses on this outcome.
- Cause. Without a placebo comparison, changes in mood during major weight loss, life change or other medicines cannot be separated from the drug.
- Course. Whether such symptoms fade with time on a stable dose is unknown.
Mood, motivation and enjoyment are not side issues: a change in any of them during treatment is information a prescriber can act on, including by reviewing the dose. Anyone with thoughts of self-harm should contact a clinician or, in the US, the 988 Suicide & Crisis Lifeline.
Sources
- PubMed searches as listed in the census table, pubmed.ncbi.nlm.nih.gov, run 2026-10-15; ClinicalTrials.gov searches "anhedonia semaglutide" (2 records) and "anhedonia tirzepatide" (3 records), run 2026-10-15.
- Nadolsky S et al. "Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: a three-case series." Obes Pillars 2026;19:100302, PubMed 42518361.
- Jamshed N et al. "Neuropsychiatric side effects of semaglutide in patients with dementia." BMJ Case Rep 2025;18(8):e262743, PubMed 40759509.
- van Bloemendaal L et al. "GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans." Diabetes 2014;63(12):4186-96, PubMed 25071023.
- Hendershot CS et al. "Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial." JAMA Psychiatry 2025;82(4):395-405, PubMed 39937469.
- Klausen MK et al. "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity." Lancet 2026;407:1687-1698, PubMed 42070571 (NCT05895643).
- Meshkat S et al. "Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review." Brain Behav 2025;15(7):e70661, PubMed 40635383.
- WEGOVY injection prescribing information, effective 2026-06-18, and ZEPBOUND prescribing information, effective 2026-08-28, sections 5 and 6, via openFDA, searched 2026-10-15.